Breaking Down Ardelyx: 7 Analysts Share Their Views
In the latest quarter, 7 analysts provided ratings for Ardelyx (NASDAQ:ARDX), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 2 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Ardelyx, presenting an average target of $16.86, a high estimate of $19.00, and a low estimate of $14.00. Surpassing the previous average price target of $13.57, the current average has increased by 24.24%.
Breaking Down Analyst Ratings: A Detailed Examination
The analysis of recent analyst actions sheds light on the perception of Ardelyx by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Caufield | HC Wainwright & Co. | Raises | Buy | $18.00 | $10.00 |
| Julian Harrison | BTIG | Maintains | Buy | $17.00 | $17.00 |
| Julian Harrison | BTIG | Maintains | Buy | $17.00 | $17.00 |
| Laura Chico | Wedbush | Raises | Outperform | $19.00 | $16.00 |
| Yigal Nochomovitz | Citigroup | Raises | Buy | $14.00 | $11.00 |
| Christopher Raymond | Piper Sandler | Raises | Overweight | $16.00 | $10.00 |
| Julian Harrison | BTIG | Raises | Buy | $17.00 | $14.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ardelyx. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ardelyx compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Ardelyx's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ardelyx's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Ardelyx analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Ardelyx Better
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Understanding the Numbers: Ardelyx's Finances
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Ardelyx showcased positive performance, achieving a revenue growth rate of 12.3% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Ardelyx's net margin is impressive, surpassing industry averages. With a net margin of -0.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ardelyx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Ardelyx's ROA stands out, surpassing industry averages. With an impressive ROA of -0.2%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 1.35, Ardelyx faces challenges in effectively managing its debt levels, indicating potential financial strain.
The Basics of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.